Globus Medical (NYSE:GMED) Releases Quarterly Earnings Results, Beats Expectations By $0.24 EPS

Globus Medical (NYSE:GMED) issued its quarterly earnings results on Thursday. The medical device company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.24, FiscalAI reports. Globus Medical had a net margin of 17.02% and a return on equity of 14.73%. The business had revenue of $789.61 million during the quarter, compared to analyst estimates of $782.88 million. During the same quarter last year, the business posted $0.86 earnings per share. Globus Medical’s revenue for the quarter was up 5.9% compared to the same quarter last year. Globus Medical updated its FY 2026 guidance to 4.950-5.050 EPS.

Here are the key takeaways from Globus Medical’s conference call:

• Positive Sentiment: Q2 revenue rose 5.9% to $789.6 million, while base-business revenue excluding Nevro increased 9%; adjusted EPS jumped 56% to a record $1.34.
• Positive Sentiment: U.S. spine grew 7%, international spine rose 14% as reported, and trauma increased 31%, supported by new products, competitive sales-force recruiting, improved inventory availability, and continued market-share gains.
• Positive Sentiment: Adjusted gross margin expanded 200 basis points to 69.4% and adjusted EBITDA margin reached 35.4%; management raised 2026 non-GAAP EPS guidance to $4.95-$5.05 while maintaining revenue guidance of $3.18-$3.22 billion.
• Negative Sentiment: Nevro sales declined 14.3% year over year and fell sequentially, while enabling-technology revenue dropped 25.8% as the company shifts toward leasing and other flexible capital-acquisition models. Management expects Nevro trial volumes to recover by late Q4, but identified both businesses as risks to second-half revenue.
• Positive Sentiment: Globus repurchased $136.1 million of shares in Q2 and has $253.9 million remaining under its authorization; it also expects to launch patient-specific SCRIPT lumbar spacers and rods in Q3, adding to a pipeline of more than 60 development projects.

Globus Medical Price Performance

Shares of NYSE GMED traded up $1.12 during midday trading on Friday, reaching $82.20. 3,299,652 shares of the stock were exchanged, compared to its average volume of 1,551,427. The business has a 50-day simple moving average of $79.33 and a two-hundred day simple moving average of $85.23. The company has a market capitalization of $11.16 billion, a price-to-earnings ratio of 21.02, a P/E/G ratio of 1.67 and a beta of 0.95. Globus Medical has a 12 month low of $54.15 and a 12 month high of $101.40.

Analysts Set New Price Targets

Several equities research analysts have recently commented on GMED shares. Truist Financial lowered their target price on Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Thursday, July 16th. Piper Sandler decreased their price target on Globus Medical from $115.00 to $100.00 and set an “overweight” rating on the stock in a report on Monday, June 15th. Zacks Research lowered Globus Medical from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Needham & Company LLC boosted their price objective on Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research report on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $101.77.

Insider Buying and Selling at Globus Medical

In related news, Director David D. Davidar sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the transaction, the director directly owned 510,175 shares in the company, valued at approximately $41,201,733. The trade was a 4.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 18.38% of the stock is owned by company insiders.

Institutional Investors Weigh In On Globus Medical

Institutional investors have recently added to or reduced their stakes in the stock. Invesco Ltd. lifted its holdings in shares of Globus Medical by 1,235.2% in the fourth quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock valued at $339,322,000 after purchasing an additional 3,595,339 shares in the last quarter. Bank of Montreal Can boosted its stake in shares of Globus Medical by 15,317.1% during the 4th quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock worth $294,519,000 after buying an additional 3,351,380 shares during the last quarter. Sculptor Capital LP grew its holdings in shares of Globus Medical by 31.9% in the 2nd quarter. Sculptor Capital LP now owns 2,760,688 shares of the medical device company’s stock valued at $162,936,000 after acquiring an additional 667,850 shares in the last quarter. Alliancebernstein L.P. grew its holdings in shares of Globus Medical by 1,303.9% in the 3rd quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock valued at $117,700,000 after acquiring an additional 1,908,795 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Globus Medical by 72.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,011,104 shares of the medical device company’s stock valued at $115,166,000 after acquiring an additional 842,547 shares in the last quarter. 95.16% of the stock is owned by institutional investors.

More Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Q2 results exceeded expectations: Globus Medical reported adjusted earnings of $1.34 per share, ahead of the approximately $1.10–$1.12 consensus, while revenue reached $789.6 million versus estimates of $782.9 million. Revenue increased 5.9% year over year, and EPS rose substantially from $0.86 in the prior-year quarter. Globus Medical Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Profit outlook improved: Management raised its fiscal 2026 EPS guidance to $4.95–$5.05, above the prior analyst consensus of $4.74. The earnings call highlighted margin gains, spine-market growth and continued benefits from operating leverage. GMED Q2 Earnings Call Highlights
• Positive Sentiment: Analyst support remains favorable: TD Cowen maintained a Buy rating and a $115 price target, citing reaccelerating spine growth, strong earnings power and robust research-and-development investment. Globus Medical Earns Buy Rating
• Neutral Sentiment: Sales outlook was unchanged: Globus Medical kept fiscal 2026 revenue guidance near $3.2 billion, roughly in line with consensus. This limits the upside from the earnings report but indicates management is maintaining its growth expectations.
• Negative Sentiment: Some execution risks remain: Management cited risks involving Nevro and Enabling Technologies, contributing to caution around revenue growth. Wells Fargo also lowered its price target from $103 to $99, although it retained an Overweight rating. Wells Fargo Analyst Action

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.